Derek T. Chalmers Sells 10,000 Shares of Cara Therapeutics Inc (NASDAQ:CARA) Stock

Cara Therapeutics Inc (NASDAQ:CARA) CEO Derek T. Chalmers sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $25.79, for a total transaction of $257,900.00. Following the sale, the chief executive officer now directly owns 918,468 shares in the company, valued at $23,687,289.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of CARA traded up $0.10 during midday trading on Wednesday, hitting $17.03. 2,483,305 shares of the company traded hands, compared to its average volume of 725,814. The stock has a 50-day moving average of $21.49 and a 200-day moving average of $21.62. Cara Therapeutics Inc has a one year low of $12.19 and a one year high of $27.55. The firm has a market cap of $1.04 billion, a P/E ratio of -8.27 and a beta of 2.30. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.21 and a quick ratio of 4.21.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.15). Cara Therapeutics had a negative net margin of 470.70% and a negative return on equity of 70.35%. The company had revenue of $5.79 million for the quarter, compared to the consensus estimate of $5.56 million. Sell-side analysts forecast that Cara Therapeutics Inc will post -2.55 EPS for the current fiscal year.

CARA has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $35.00 price objective on shares of Cara Therapeutics in a report on Tuesday. BidaskClub raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Cara Therapeutics in a report on Tuesday. Zacks Investment Research downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 8th. Finally, ValuEngine raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $27.54.

Institutional investors and hedge funds have recently made changes to their positions in the company. Aperio Group LLC bought a new stake in shares of Cara Therapeutics during the second quarter valued at about $88,000. Russell Investments Group Ltd. bought a new stake in shares of Cara Therapeutics during the third quarter valued at about $110,000. Penserra Capital Management LLC bought a new position in shares of Cara Therapeutics in the third quarter worth approximately $180,000. Squarepoint Ops LLC bought a new position in shares of Cara Therapeutics in the third quarter worth approximately $190,000. Finally, Sfmg LLC bought a new position in shares of Cara Therapeutics in the second quarter worth approximately $200,000. Hedge funds and other institutional investors own 76.08% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Featured Story: Dow Jones Industrial Average (DJIA)

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.